For Medical Practitioners

Alzheimer’s disease is actually several different diseases. Each has its own optimal treatment. ReCODE makes treating each possible.

Why choose AHNP? We support physicians and patients by providing dynamic, evolving solutions for cognitive decline, and empower practitioners to mitigate their patients’ risk for cognitive decline before it even starts.

ReCODE Medical Information Includes:

  • Complete training in The ReCODE Protocol, a comprehensive and customizable protocol for the reversal of cognitive decline in individuals with early Alzheimer’s disease, mild cognitive impairment (MCI), subjective cognitive impairment (SCI), or at risk for cognitive decline (Bredesen, Aging 2014; Bredesen, Aging 2015; Bredesen, Aging 2016).
  • The ReCODE Report software, which evaluates large data sets of genomic, biochemical, functional, and radiological data with respect to the major types of Alzheimer’s disease (Bredesen, Aging 2015) and other conditions. The ReCODE Report software determines which subtype of Alzheimer’s disease the patient has or is at risk for, and develops a personalized protocol for reversal and prevention.
  • Optimal tests for evaluation, treatment, and follow-up tracking for patients, no matter where they fall on the cognitive decline spectrum.
  • Lists of tests that can identify genetic, biometric, hormonal, and lifestyle factors contributing to cognitive decline.
  • Supplemental information for coaches, patients, nutritionists, physical therapists, and other team members.
  • Training on the ReCODE Report software.

In collaboration with AHNP, The Institute for Functional Medicine will be training practitioners in The ReCODE Protocol™.


Keep up to date with Dr. Bredesen's latest research

Reversal of Cognitive Decline: 100 Patients
The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline, using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline. READ MORE

Reversal of Cognitive Decline in Alzheimer’s Disease
Alzheimer’s disease is one of the most significant healthcare problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published.  The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neurodegeneration (MEND). Patients who had to discontinue work were able to return to work, and those struggling at work were able to improve their performance. The patients, their spouses, and their co‐workers all reported clear improvements. READ MORE


Get In Touch

We would love to hear from you. Contact us by clicking the Help button with any questions or call us at 1.800.450.0805.

Due to increased interest in the ReCODE Report and ReVERSE Program, you may experience a delay in response time.

Terms of Service | Privacy Statement